Chronic inflammatory diseases, including psoriasis, require therapeutic approaches that maintain efficacy and tolerability even during long-term treatment. One such modern modality is brodalumab, a fully human monoclonal antibody against the A subunit of the interleukin (IL) 17 receptor. A study published last year evaluated its long-term efficacy and safety in patients with moderate to severe plaque psoriasis and also focused on improving their quality of life.
Don‘t have an account? Create new account
Enter the email address that you registered with. We will send you instructions on how to set a new password.
